On Longevity.Technology's podcast, the two contrast well-studied GLP-1 drugs with thinly tested compounds and discuss gray-market risks and testing.
Recap by typeshit. Full story at Longevity.Technology.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A consumer review of Lemonaid's telehealth weight loss service, which manages GLP-1 injections and prescriptions for patients paying out of pocket.
In 194 adults who moved from injectable semaglutide or tirzepatide to oral semaglutide, 40.7% lost at least 5% more in three months. Data shown at EASD, not yet peer reviewed.
Loading…